{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:43:49Z","timestamp":1791945829988,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,14]],"date-time":"2017-01-14T00:00:00Z","timestamp":1484352000000},"content-version":"am","delay-in-days":410,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Institutes of Health\u2019s Minority Biomedical Research Support (MBRS)-SC1 program","award":["SC1 GM092779\u201301"],"award-info":[{"award-number":["SC1 GM092779\u201301"]}]},{"name":"National Institute on Minority Health and Health Disparities (NIMHD) P20 programNational Institute on Minority Health and Health Disparities (NIMHD) P20 program","award":["1P20 MD006738\u201303"],"award-info":[{"award-number":["1P20 MD006738\u201303"]}]},{"name":"Department of Defense (DOD) Breast Cancer ProgramDepartment of Defense (DOD) Breast Cancer Program","award":["W81XWH-11\u20131\u20130211"],"award-info":[{"award-number":["W81XWH-11\u20131\u20130211"]}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1002\/jps.24637","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T20:55:50Z","timestamp":1442350550000},"page":"4417-4426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer"],"prefix":"10.1016","volume":"104","author":[{"given":"Ketan","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nusrat","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Doddapaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedar H.A.","family":"Boakye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandraiah","family":"Godugu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandip","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1\u20133","key":"10.1002\/jps.24637_bb0005","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejphar.2013.02.058","article-title":"Taxanes: Old drugs, new oral formulations","volume":"717","author":"Jibodh","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1002\/jps.24637_bb0010","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/CAD.0b013e3280113338","article-title":"Alternative drug formulations of docetaxel: A review","volume":"18","author":"Engels","year":"2007","journal-title":"Anti-Cancer Drugs"},{"issue":"1\u20132","key":"10.1002\/jps.24637_bb0015","first-page":"99","article-title":"Current treatment options in triple negative breast cancer","volume":"32","author":"Rodler","year":"2010","journal-title":"Breast Dis"},{"issue":"Suppl 2","key":"10.1002\/jps.24637_bb0020","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.3816\/CBC.2009.s.008","article-title":"Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer","volume":"9","author":"Anders","year":"2009","journal-title":"Clin Breast Cancer"},{"issue":"Suppl 1","key":"10.1002\/jps.24637_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S1-01","article-title":"Triple-negative breast cancer: An unmet medical need","volume":"16","author":"Hudis","year":"2011","journal-title":"The Oncologist"},{"issue":"7","key":"10.1002\/jps.24637_bb0030","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1002\/jps.24637_bb0035","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/ijc.27912","article-title":"P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel","volume":"132","author":"Hendrikx","year":"2013","journal-title":"Int J Cancer J Int Du Cancer"},{"issue":"1\u20132","key":"10.1002\/jps.24637_bb0040","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijpharm.2014.06.031","article-title":"Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: Preparation, characterization and antitumor activity","volume":"472","author":"Patel","year":"2014","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1002\/jps.24637_bb0045","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1365-2125.2010.03621.x","article-title":"Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer","volume":"69","author":"Koolen","year":"2010","journal-title":"Brit J Clin Pharmacol"},{"issue":"2","key":"10.1002\/jps.24637_bb0050","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1574884708666131111193403","article-title":"Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancer","volume":"9","author":"Helgason","year":"2014","journal-title":"Curr Clin Pharmacol"},{"issue":"11","key":"10.1002\/jps.24637_bb0055","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1038\/bjc.2014.222","article-title":"Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation","volume":"110","author":"Hendrikx","year":"2014","journal-title":"Brit J Cancer"},{"issue":"9","key":"10.1002\/jps.24637_bb0060","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1023\/A:1025774630993","article-title":"Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line","volume":"20","author":"Haynes","year":"2003","journal-title":"Pharm Res"},{"issue":"1","key":"10.1002\/jps.24637_bb0065","first-page":"65","article-title":"15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel antitumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors","volume":"18","author":"Fulzele","year":"2007","journal-title":"Anti-Cancer Drugs"},{"issue":"9","key":"10.1002\/jps.24637_bb0070","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1007\/s11095-006-9074-6","article-title":"Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model","volume":"23","author":"Fulzele","year":"2006","journal-title":"Pharm Res"},{"issue":"11","key":"10.1002\/jps.24637_bb0075","doi-asserted-by":"crossref","first-page":"e27394","DOI":"10.1371\/journal.pone.0027394","article-title":"Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer","volume":"6","author":"Chougule","year":"2011","journal-title":"PLoS ONE"},{"issue":"7355","key":"10.1002\/jps.24637_bb0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature10167","article-title":"Selective killing of cancer cells by a small molecule targeting the stress response to ROS","volume":"475","author":"Raj","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1002\/jps.24637_bb0085","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/bjc.2013.810","article-title":"Piperlongumine promotes autophagy via inhibition of Akt\/mTOR signalling and mediates cancer cell death","volume":"110","author":"Makhov","year":"2014","journal-title":"Brit J Cancer"},{"key":"10.1002\/jps.24637_bb0090","doi-asserted-by":"crossref","first-page":"906804","DOI":"10.1155\/2014\/906804","article-title":"Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells","volume":"2014","author":"Gong","year":"2014","journal-title":"Oxidative Med Cell Longevity"},{"issue":"11","key":"10.1002\/jps.24637_bb0095","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1124\/dmd.110.033894","article-title":"Effect of regular organic solvents on cytochrome P450-mediated metabolic activities in rat liver microsomes","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1002\/jps.24637_bb0100","doi-asserted-by":"crossref","first-page":"e89919","DOI":"10.1371\/journal.pone.0089919","article-title":"Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid","volume":"9","author":"Godugu","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1002\/jps.24637_bb0105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/dmd.110.034629","article-title":"Attenuation of intestinal absorption by major efflux transporters: Quantitative tools and strategies using a Caco-2 model","volume":"39","author":"Lin","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1002\/jps.24637_bb0110","doi-asserted-by":"crossref","first-page":"e17733","DOI":"10.1371\/journal.pone.0017733","article-title":"Antitumor activity of Noscapine in combination with Doxorubicin in triple negative breast cancer","volume":"6","author":"Chougule","year":"2011","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1002\/jps.24637_bb0115","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2010.06.002","article-title":"Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer","volume":"71","author":"Chougule","year":"2011","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1002\/jps.24637_bb0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nprot.2007.30","article-title":"In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro","volume":"2","author":"Liang","year":"2007","journal-title":"Nat Protocols"},{"issue":"12","key":"10.1002\/jps.24637_bb0125","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1166\/jbn.2013.1710","article-title":"Medium chain triglyceride (MCT) rich, paclitaxel loaded self nanoemulsifying preconcentrate (PSNP): A safe and efficacious alternative to Taxol","volume":"9","author":"Patel","year":"2013","journal-title":"J Biomed Nanotechnol"},{"issue":"1","key":"10.1002\/jps.24637_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200342010-00003","article-title":"Role of P-glycoprotein in pharmacokinetics: Clinical implications","volume":"42","author":"Lin","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1002\/jps.24637_bb0135","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2001.19.4.1160","article-title":"Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel","volume":"19","author":"Malingre","year":"2001","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1002\/jps.24637_bb0140","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1002\/jps.22157","article-title":"Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation","volume":"99","author":"Ganta","year":"2010","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1002\/jps.24637_bb0145","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.2042-7158.2010.01129.x","article-title":"Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats","volume":"62","author":"Choi","year":"2010","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"10.1002\/jps.24637_bb0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejps.2011.11.021","article-title":"Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats","volume":"45","author":"Park","year":"2012","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"10.1002\/jps.24637_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpharm.2006.05.046","article-title":"Altered pharmacokinetics of paclitaxel by the concomitant use of morin in rats","volume":"323","author":"Choi","year":"2006","journal-title":"Int J Pharm"},{"issue":"31","key":"10.1002\/jps.24637_bb0160","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1038\/onc.2010.198","article-title":"MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells","volume":"29","author":"Chen","year":"2010","journal-title":"Oncogene"},{"issue":"50","key":"10.1002\/jps.24637_bb0165","doi-asserted-by":"crossref","first-page":"38832","DOI":"10.1074\/jbc.M110.124958","article-title":"Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1","volume":"285","author":"Luanpitpong","year":"2010","journal-title":"J Bio Chem"},{"issue":"14","key":"10.1002\/jps.24637_bb0170","first-page":"3976","article-title":"Targeting of methotrexate-containing liposomes with a monoclonal antibody against human renal cancer","volume":"49","author":"Singh","year":"1989","journal-title":"Cancer Res"},{"issue":"Suppl 6","key":"10.1002\/jps.24637_bb0175","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mds187","article-title":"Triple-negative breast cancer: Epidemiological considerations and recommendations","volume":"23","author":"Boyle","year":"2012","journal-title":"Annal Oncol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,18]],"date-time":"2023-07-18T12:44:15Z","timestamp":1689684255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0022354915000702"],"URL":"https:\/\/doi.org\/10.1002\/jps.24637","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/jps.24637","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Wiley Periodicals, Inc. and the American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}